

Phage Therapy of *Mycobacterium* Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease

Rebekah M. Dedrick,¹ Bailey E. Smith,¹ Madison Cristinziano,¹ Krista G. Freeman,¹ Deborah Jacobs-Sera,¹ Yvonne Belessis,^{2,3} A. Whitney Brown,⁴ Keira A. Cohen,⁵ Rebecca M. Davidson,⁶ David van Duin,⁷ Andrew Gainey,⁸ Cristina Berastegui Garcia,⁹ C. R. Robert George,¹⁰ Ghady Haidar,¹¹ Winnie Ip,¹² Jonathan Iredell,¹³ Ameneh Khatami,^{14,15} Jessica S. Little,¹⁶ Kirsi Malmivaara,¹⁷ Brendan J. McMullan,¹³ David E. Michalik,¹⁸ Andrea Moscatelli,¹⁹ Jerry A. Nick,²⁰ Maria G. Tupayachi Ortiz,²¹ Hari M. Polenakovic,²² Paul D. Robinson,²³ Mikael Skurnik,^{24,25} Daniel A. Solomon,¹⁶ James Soothill,¹⁷ Helen Spencer,²⁶ Peter Wark,²⁷ Austen Worth,¹² Robert T. Schooley,²⁸ Constance A. Benson,^{28,a} and Graham F. Hatfull^{1,a}

¹Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ²School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia; ³Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, New South Wales, Australia; ⁴Inova Fairfax Hospital, Falls Church, Virginia, USA; ⁵Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; ⁶Center for Genes, Environment, and Health, National Jewish Health, Denver, Colorado, USA; ⁷Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA; ⁸Department of Pharmacy, Division of Pediatric Infectious Diseases, Prisma Health Children's Hospital—Midlands, Columbia, South Carolina, USA; ⁹Department of Respiratory Disease, Hospital Universitari Vall d'Hebron, Barcelona, Spain; ¹⁰New South Wales Health Pathology Microbiology, John Hunter Hospital, New Lambton, New South Wales, Australia; ¹¹Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; ¹²Department of Pediatric Immunology, Great Ormond Street Hospital, London, United Kingdom; ¹³Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia; ¹⁴Department of Infectious Diseases and Microbiology, Children's Hospital at Westmead, Westmead, New South Wales, Australia; ¹⁵Discipline of Child and Adolescent Health, University of Sydney, Sydney, New South Wales, Australia; ¹⁶Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA; ¹⁷Great Ormond Street Hospital, London, United Kingdom; ¹⁸Miller Children's and Women's Hospital, Division of Pediatric Infectious Diseases, Long Beach, California, USA; ¹⁹Neonatal and Pediatric Intensive Care Unit, Istituto Giannina Gaslini, Genoa, Italy; ²⁰Department of Medicine, National Jewish Health, Denver, Colorado, USA; ²¹Department of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA; ²²Internal Medicine Department, Dayton Children's Hospital, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA; ²³Department of Respiratory Medicine, The Children's Hospital at Westmead, Westmead, New South Wales, Australia; ²⁴Department of Bacteriology and Immunology, Human Microbiome Research Program, University of Helsinki, Helsinki, Finland; ²⁵Division of Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland; ²⁶Respiratory Medicine and Cardiothoracic Transplantation, Great Ormond Street Hospital, London, United Kingdom; ²⁷Immune Health Program, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia; and ²⁸Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA

Background. Nontuberculous *Mycobacterium* infections, particularly *Mycobacterium abscessus*, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among *M. abscessus* isolates, requiring personalized phage identification.

Methods. *Mycobacterium* isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid.

Results. No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these.

Conclusions. Phage treatment of *Mycobacterium* infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.

Keywords. phage therapy; nontuberculous mycobacteria; mycobacteriophage.

Received 08 April 2022; editorial decision 24 May 2022; published online 9 June 2022

^aC. A. B. and G. F. H. contributed equally to this work.

Correspondence: G. Hatfull, Department of Biological Sciences, University of Pittsburgh, 4249 5th Avenue, Pittsburgh, PA 15260 (gfh@pitt.edu).

Clinical Infectious Diseases® 2023;76(1):103–12

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

<https://doi.org/10.1093/cid/ciac453>

The therapeutic use of phages for treating drug-resistant bacterial infections has received recent attention, but the types of infections and pathogens deemed suitable; routes, dosage, and frequency of administration; interactions with antibiotics; and pharmacokinetics remain unclear [1, 2]. Unlike small molecule antibiotics, bacteriophages can replicate at the sites of infection, are much larger than standard antimicrobials, and penetration to sites of bacterial replication may be restricted. Immune neutralization may also limit phage activity [3].

Bacteriophages are often highly bacterium-specific, which is advantageous for precise pathogen targeting, but demands personalized phage matching for individual patient isolates [3]. Anecdotal reports support a robust safety profile and clinical improvement has been reported for some but not all cases [4–7].

Because of increasing and widespread antibiotic resistance among *Mycobacterium* pathogens, alternative therapies are needed [8–10]. Nontuberculous mycobacterial (NTM) infections—especially those caused by *Mycobacterium abscessus*—are particularly challenging, as many are refractory to antibiotics and extended drug therapies are poorly tolerated [11]. NTM infections are increasingly common among people with cystic fibrosis (CF), but are also prevalent among non-CF patients, including those with bronchiectasis or Mendelian susceptibility to mycobacterial disease (MSMD) [12, 13]. People with CF typically have complex recurrent pulmonary infections, often with mixed flora, but *M. abscessus* infections are particularly challenging and typically preclude lung transplantation. Phages have been proposed for managing CF [14], but their utility for *Mycobacterium* infections, including NTM and tuberculosis [3, 15, 16], remains unclear.

There is great variation in phage susceptibilities among *M. abscessus* clinical isolates [17]. Approximately 40% of *M. abscessus* isolates have a smooth colony morphotype [17, 18], and to date no therapeutically useful phages have been identified for these [17]. In contrast, 75%–80% of rough strains are efficiently killed by at least 1 phage, and the low rates of phage resistance in vitro suggest that phage resistance in vivo may not be a limitation [17]. Nonetheless, the repertoire of therapeutically useful phages is small, and mostly limited to phages isolated on *Mycobacterium smegmatis*; few phages have been isolated directly on any strain of *M. abscessus* [5].

Two case reports have described compassionate use of phages for NTM infections [5, 19]. One was a patient with CF and disseminated *M. abscessus* infection following bilateral lung transplantation and drug-induced immunosuppression [5]. The second was an immunocompetent patient with non-CF bronchiectasis and a severe *M. abscessus* pulmonary infection [19]. The same 3-phage cocktail was used to treat both patients and was administered intravenously (IV) twice daily at a dose of 10^9 plaque-forming units (PFUs) per dose for at least 6 months. Both were also treated with concomitant multidrug antibiotic regimens. The first patient had clinical improvement in lung function, radiographic imaging, and clinical signs and symptoms, although without complete clearance of the infection [5]. The second had initial reduction in *M. abscessus* colony counts in sputum that was abrogated by emergence of a potent neutralizing antibody response to the phages [19].

We report here therapeutic interventions for a pilot cohort of 20 patients with antibiotic-refractory mycobacterial infections. Phage administration was safe, no resistance was observed, and

favorable microbiological or clinical outcomes were observed in a majority of cases.

METHODS

Identification and Evaluation of Patients Suitable for Compassionate Use Phage Treatment

Since May 2019, we received approximately 200 requests for adjunctive phage treatment for patients with NTM infections that were either refractory to antibiotic therapies or in which extended drug treatments were not tolerated; antibiotic susceptibilities are shown in [Supplementary Table 1](#). Most patients had CF and *M. abscessus* infections, but some had other underlying diseases complicated by NTM (and in 1 case bacille Calmette-Guerin [BCG]) infections. The following criteria determined eligibility for compassionate use phage therapy: age >5 years, microbiologic documentation of mycobacterial infection based on at least 2 positive cultures of relevant tissue or body fluids; drug susceptibility testing (DST) documenting resistance to multiple antimycobacterial drugs; clinical signs, symptoms and radiographic findings involving at least 1 organ system (eg, NTM lung disease based on American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA) diagnostic criteria [20]) or evidence of disseminated disease; clinical failure of or intolerance to antimycobacterial treatment; stable underlying conditions with anticipated survival of at least 3 months; and treating physician(s) able and willing to use adjunctive phage therapy. Recent mycobacterial isolates from patients were screened for phages that efficiently infect and kill the isolate, and regulatory approval was provided under an emergency Investigational New Drug application by the United States Food and Drug Administration or comparable processes outside of the United States. Local investigational or ethics review board approvals were also obtained. Twenty patients who met criteria provided informed consent for adjunctive phage therapy ([Table 1](#)). See the [Supplementary Information](#) for detailed methods.

Phage Administration

With relatively few potentially therapeutically useful phages for NTM [17], in 11 cases only a single candidate phage was identified; for others, 2 or more genomically distinct phages were combined into cocktails ([Tables 1 and 2](#)). Most patients were initially administered 10^9 PFU intravenously twice daily; some patients also received the same dose by inhalational nebulization ([Table 1](#)). All patients also received antimycobacterial treatment with at least 2 drugs based on prior DST against their own target isolate and on their prior tolerance of available drugs. Initial duration of phage treatment was 6 months, although some patients received shorter or longer courses of

Table 1. Profiles of 20 Patients Treated for *Mycobacterium* Infections With Phages

Patient No., Origin, Strain	Age	Underlying Condition	Type of Infection	Organism	Phages Used	Route of Administration (Duration)	Key Clinical Data and Outcomes
Favorable or partial responses							
1, UK GD01	Pediatric	CF, bilateral lung transplant	Disseminated (lung, skin and liver nodules, sternal bone infection)	<i>Mycobacterium abscessus</i> subsp <i>massiliense</i>	BPsΔ33HTH_HRM10, Muddy, ZoeJΔ45	IV, topical (3.5 y)	Resolution of infected liver and skin nodules; sternal wound closure; intermittent smear and culture negative; patient died due to multiple transplant complications
2, USA GD10	Adult	Scleroderma, lung transplant	Lung, sternal bone infection	<i>M. abscessus</i> subsp <i>massiliense</i>	Muddy	IV, chest wash (1 m)	Swab samples became AFB smear negative/rare; patient died due to multiple underlying coinfections
4, Italy GD24	Pediatric	CF, lung transplant	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM ^{GD03}	IV (1 m)	Conversion to AFB smear negative; patient died due to adenovirus systemic infection
7, Australia GD43	Pediatric	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i> (both smooth and rough colonies isolated; only rough colony morphotype susceptible to phage)	BPsΔ33HTH_HRM ^{GD03}	IV (7 m)	Culture conversion to negative for rough colony strain, but smooth strain still present; improvement in some clinical signs and symptoms
9, Australia GD54	Pediatric	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	Muddy, BPsΔ33HTH_HRM ^{GD03}	IV, Bronchoscopic administration (1 y)	After 10 mo of IV therapy and 2 phase bronchoscopic administrations, patient was AFB smear and culture negative; infection resolved
10, Spain GD57	Adult	CF, lung transplant	Lung, disseminated infection post-lung transplant	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM ^{GD03} , Itos	IV (1 y)	Culture and smear conversion; improved FEV ₁ and resolution of infection
13, Finland GD102	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	Muddy	Course 1: IV (10 m) Course 2: Aerosol (4 wk)	Patient had FEV ₁ improvement but remained AFB culture positive; switched to aerosolized phage therapy
15, USA GD116	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM10, D29_HRM ^{GD40}	IV (1.1 y, ongoing)	After 12 mo of IV phage therapy, culture negative and eligible for lung transplant. Patient was transplanted October 2021; no recurrence
16, USA GD153	Adult	Seronegative arthritis on immunosuppression	Disseminated cutaneous infection	<i>Mycobacterium chelonae</i>	Muddy	IV (9 m, ongoing)	Skin nodules significantly improved and tissue culture and histopathology negative for organism after 3 mo of IV phage
17, USA GD156	Pediatric	CF	Lung	<i>Mycobacterium avium</i> complex	Muddy	Course 1: IV (3 m) Course 2: Aerosol (ongoing)	FEV ₁ improvement of >15% was seen in first month of IV phage treatment; time to positivity increased from 1 wk prior to treatment to 4–8 wk posttreatment; consecutive AFB cultures obtained at 21 and 25 wk after treatment have shown no growth

Table 1. Continued

Patient No., Origin, Strain	Age	Underlying Condition	Type of Infection	Organism	Phages Used	Route of Administration (Duration)	Key Clinical Data and Outcomes
20, UK BCG	Pediatric	Heterozygous mutation in <i>NFKB1A</i> gene c.32 G > A; p.(Trp11*), MSMD	Disseminated BCG mycobacterial infection	BCG	Muddy, D29, FionnbarthΔ43Δ45, Fred313cpmΔ33	IV (1.7 y)	Reduction in fever and systemic inflammation; improved BCG PCR cycle threshold in cultures. Patient died from other infections
Complex, inconclusive, or incomplete responses							
3, USA GD20	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM10, Itos	IV (both phages, 2 dl Break 18 d IV (BPsΔ33HTH_HRM10 only, 8 d)	Patient died due to multiple organ failure
8, USA GD45	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	Muddy	Course 1: Aerosol (3 m) Course 2: IV + Aerosol at 10 ¹⁰ PFU/dose (7 m) Course 3: Aerosol at 10 ¹⁰ PFU/dose (3 m) Course 4: Aerosol Muddy and BPs (2 m, ongoing)	No clinical improvement with aerosolized phage, IV delivery added, and patient became intermittently smear negative; patient mounted a neutralizing antibody response, although was intermittently smear negative. Patient was switched to aerosolized phage only
11, USA GD68	Pediatric	CF	Lung	<i>M. abscessus</i> subsp <i>massiliense</i> (both smooth and rough colony morphologies; only rough was treated with phage)	Muddy	IV (1.7 y, ongoing)	Improved chest scans, but intermittently AFB smear and culture positive
12, USA GD82	Adult	Chronic lung bronchiectasis	Lung	<i>M. abscessus</i> subsp <i>massiliense</i>	BPsΔ33HTH_HRM10, Muddy, ZoeJΔ45	Course 1: IV (6 m) Course 2: Aerosol (12 m, discontinued in terminal illness)	Little clinical improvement with IV phage therapy; potent phage neutralization; switched to aerosolized phage; phage therapy continued through terminal illness; patient died in hospice
18, USA GD158	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>massiliense</i>	Muddy	Course 1: IV (4 m) Course 2: IV and aerosol (ongoing)	Little clinical improvement with IV phage therapy; potent phage neutralization; added aerosolized phage; treatment ongoing
No evident clinical improvement							
5, USA GD25	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	Muddy	Course 1: IV (3 m) Break 2 m Course 2: Aerosol (8 m)	No substantial clinical improvement after IV or aerosolized treatment
6, Australia GD40	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM ^{GB03}	IV (6 m)	No substantial clinical improvement after 6 mo IV treatment
14, Spain GD113	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM ^{GD03} , D29_HRM ^{GD40}	IV (11 m, ongoing)	No clinical improvement after 11 mo
19, USA GD194	Adult	CF	Lung	<i>M. abscessus</i> subsp <i>abscessus</i>	BPsΔ33HTH_HRM10, Itos	Course 1: IV (5 m) Course 2: Aerosol (<1 m, ongoing)	No substantial clinical improvement after 3 months of IV phage. Patient was switched to aerosolized phage treatment; ongoing

Abbreviations: AFB, acid-fast bacilli; BCG, bacille Calmette-Guérin; CF, cystic fibrosis; FEV₁, forced expiratory volume at 1 second; IV, intravenous; MSMD, Mendelian susceptibility to mycobacterial disease; PCR, polymerase chain reaction; PFU, plaque-forming units; UK, United Kingdom; USA, United States of America.

Table 2. Therapeutic Phages and Phage Sensitivities of Posttreatment *Mycobacterium* Isolates

Phages ^a	No. of Patients Treated	Phage Susceptibility of Phage Treatment Isolates ^{b,c}
Muddy	8	S – Patients 2, 5, 8, 11 (smooth and rough) ^d , 13, 18 NA – Patient 16 NT – Patient 17
BPsΔ33HTH_HRM ^{GD03}	3	Only non-susceptible smooth strain recovered post treatment – Patient 7 ^d NT – Patients 4, 6
Muddy, BPsΔ33HTH_HRM ^{GD03}	1	NA – Patient 9
Muddy, BPsΔ33HTH_HRM10, ZoeJΔ45	2	S (BPsΔ33HTH_HRM10 and Muddy) – Patients 1, 12; PR (ZoeJΔ45) – Patients 1, 12
BPsΔ33HTH_HRM ^{GD03} , Itos	1	NT – Patient 10
BPsΔ33HTH_HRM10, Itos	2	S – Patient 19 NT – Patient 3
BPsΔ33HTH_HRM10, D29_HRM ^{GD40}	1	S – Patient 15
BPsΔ33HTH_HRM ^{GD03} , D29_HRM ^{GD40}	1	NT – Patient 14
Muddy, D29, FionnbarthΔ43Δ45, Fred313cpmΔ33	2	NT – Patient 20

Abbreviations: NA, not applicable (no posttherapy isolates were grown); NT, not tested; PR, partially resistant; S, sensitive.

^aPhages were used therapeutically either singly, or in the combinations shown.

^bPatient numbers are as shown in Tables 1 and 3.

^cStrains from patients were tested for changes in phage sensitivity. Strains were initially sensitive to the phages used therapeutically. For each patient, strains isolated after the start of phage treatment are shown as being phage sensitive, partially resistant, or not tested. Multiple samples from the same patients were tested similarly.

^dIndicates patient with a mixed smooth and rough colony morphology *Mycobacterium abscessus* infection. For patient 11, both smooth and rough morphotypes were recovered during treatment and both morphotypes remained fully susceptible to Muddy, although the smooth strain is not killed by Muddy. For patient 7, only smooth isolates were found intratreatment, and only smooth isolates were tested for phage susceptibility.

treatment directed by clinical and microbiologic responses (Table 1). When available, baseline clinical and laboratory assessments of patients included signs and symptoms of NTM infection, a complete blood count, renal and liver chemistries, sedimentation rate, and C-reactive protein, and, when applicable, radiographic assessment and pulmonary function studies. Where possible, these were monitored weekly during the first month of phage treatment and monthly thereafter; radiographic and pulmonary functions were evaluated at intervals determined by treating clinicians. Microbiological monitoring included acid-fast bacilli (AFB) smear and culture of sputum or other relevant clinical specimens at baseline, at 1 month, and then periodically thereafter based on clinical and microbiologic response. During treatment, *Mycobacterium* strains from clinical samples were tested for phage resistance (Table 2). Where possible, serum, sputum, and/or bronchoalveolar lavage specimens were collected prior to and after treatment initiation and tested for phage antibodies using neutralization or enzyme-linked immunosorbent assays or both (Table 3). For several patients, both serum and sputum samples were tested by polymerase chain reaction (PCR) for the presence of phage DNA; only sporadic weakly positive signals were observed (Supplementary Figure 1). Antimycobacterial regimens were adjusted by the treating clinicians as needed based on DST and drug tolerability during phage treatment.

RESULTS

Personalization of Bacteriophage Regimens

Mycobacterial isolates from individual patients were tested for sensitivity to a panel of approximately 25 phages

representing genomic clusters known to infect *M. abscessus* or *Mycobacterium tuberculosis* (Figure 1) [5, 17, 21]. Of the 200 strains screened between May 2019 and May 2021, 157 (78%) were *M. abscessus*; 77 and 71, respectively, had rough and smooth colony morphologies; 9 were mixed and both types were purified and cultured. Fifty-five (71%) rough colony strains were infected and killed efficiently by at least 1 phage. If an isolate was efficiently infected and killed by 1 or more phage, and the patient's clinical status indicated eligibility for compassionate use intervention as previously described, regulatory permissions were obtained and purified phages were dispatched to a local dispensing pharmacy. Of the 20 patients offered treatment, 17 had *M. abscessus* infections; 14 of these had underlying CF, 1 had bronchiectasis, 1 had scleroderma, and 1 had hypersensitivity pneumonitis. One patient had a *Mycobacterium chelonae* disseminated skin infection, 1 had CF with pulmonary *Mycobacterium avium*, and 1 had a disseminated BCG infection (Table 1). Of the 17 *M. abscessus* strains isolated, 12 were subspecies *abscessus* and 5 were subspecies *massiliense* (Table 1).

Patient Outcomes

All patients were treated based on compassionate use, had disparate underlying conditions, and had complex infections due to diverse mycobacterial species with differing patterns of phage and antimicrobial susceptibility. Therefore, fixed definitions of treatment response were not possible. Generally, a favorable response was defined as mycobacterial smear and culture conversion to negative in at least 1 relevant specimen coupled with clinical and/or radiographic improvement or

Table 3. Serum and Sputum Phage Neutralization

Patient ^a	Strain	Immune Status	Sample	Phage	Neutralization ^b	Pre-phage ELISA Log Half-Maximum Titer ^c	Maximum Observed ELISA Log Half-Maximum Titer ^c
1	GD01	IS	Serum	Muddy	Y (2.3 y)	NA	NA
				BPsΔ33HTH_HRM10	N	NA	NA
				ZoeJΔ45	N	NA	NA
3	GD20	IC	Serum	BPsΔ33HTH_HRM10	N	2.8	3.5 (24 h)
				Itos	N	NA	NA
			Sputum	BPsΔ33HTH_HRM10	N	1.8	3.4 (3 wk)
				Itos	N	NA	NA
5	GD25	IC	Serum	Muddy	N	NA	NA
7	GD43	IC	Serum	BPsΔ33HTH_HRM ^{GD03}	N	NA	NA
				BAL	BPsΔ33HTH_HRM ^{GD03}	N	NA
8	GD45	IC	Serum	Muddy	Y (1 m)	4.3	4.6 (1 m IV)
				Sputum	Muddy	N	NA
9	GD54	IC	Serum	Muddy	N	NA	NA
				BPsΔ33HTH_HRM ^{GD03}	N	NA	NA
10	GD57	IS	Serum	BPsΔ33HTH_HRM ^{GD03}	Y (7 d)	NA	NA
				Itos	Y (7 d)	NA	NA
11	GD68	IC	Serum	Muddy	Y (1 m)	3.7	4.3 (3 m)
12	GD82	IC	Serum	Muddy	Y (2 m)	2.9	4.9 (5 m IV)
				BPsΔ33HTH_HRM10	Y (2 m)	0	5.3 (5 m neb)
				ZoeJΔ45	Y (2 m)	1.7	4.7 (5 m neb)
			Sputum	Muddy	N	NA	2.9 (3 m neb)
				BPsΔ33HTH_HRM10	N	NA	2.9 (3 m neb)
				ZoeJΔ45	N	NA	2.9 (3 m neb)
13	GD102	IC	Serum	Muddy	N	NA	NA
14	GD113	IC	Serum	BPsΔ33HTH_HRM ^{GD03}	W (7 d)	NA	NA
				D29_HRM ^{GD40}	W (14 d)	NA	NA
15	GD116	IC	Serum	BPsΔ33HTH_HRM10	Y (149 d)	3.3	4.0 (269 d)
				D29_HRM ^{GD40}	W (269 d)	3.2	3.7 (149 d)
16	GD153	IS	Serum	Muddy	Y (17 d)	2.3	4.4 (16 wk)
17	GD156	IC	Serum	Muddy	N	NA	NA
18	GD158	IC	Serum	Muddy	Y (45 d)	2.7	5.0 (15 w IV)
19	GD194	IC	Serum	BPsΔ33HTH_HRM10	Y (8 wk)	NA	NA
				Itos	Y (8 wk)	NA	NA
20	BCG	MSMD	Serum	Muddy	N	NA	NA
				D29	N	NA	NA
				FionnbharthΔ43Δ45	N	NA	NA
				Fred313cpmΔ33	N	NA	NA

Abbreviations: BAL, bronchoalveolar lavage fluid; BCG, bacille Calmette-Guerin; ELISA, enzyme-linked immunosorbent assay; IC, immunocompetent; IS, immunosuppressed; IV, intravenous; MSMD, Mendelian susceptibility to mycobacterial disease; N, no; NA, not applicable; neb, nebulization; W, weak; Y, yes.

^aOnly data for patients for whom serum or sputum was available.

^bBinary indicator of neutralization. Neutralization is defined as $>10^3$ reduction in titer in 24 hours. Time after phage initiation of the earliest sample available with neutralization is shown in parentheses. No pre-phage samples were neutralizing for any patient.

^cSerum ELISAs show immunoglobulin G responses; sputum ELISAs show immunoglobulin A responses. Maximum observed ELISA titer at time after phage initiation is shown in parentheses.

resolution of signs and symptoms of infection after at least 6–8 weeks of phage treatment. A partial response was defined as either mycobacterial smear or culture conversion or clinical and radiographic improvement. All patients had a previous history of prolonged or relapsing mycobacterial infections often coupled with other drug-resistant bacterial coinfections, underlying organ system consequences of CF or chronic lung disease, and numerous other clinical complications. Patients with CF were generally not receiving or had failed

CF transmembrane conductance regulator modulators. Antibiotic therapies were optimized where possible, although most patients had only 1 or 2 at least partially active antibiotics that were used with phages. Underlying conditions and drug toxicities complicated interpretation of phage efficacy in several patients. Within this context, of the 20 patients treated, favorable or partially favorable responses were observed for 11 patients, 5 had inconclusive outcomes, and 4 had no response (Tables 1–3). Groups of patients with differing responses to




Figure 1. Scheme for identifying therapeutically suitable mycobacteriophages. Clinical isolates on slants (top) are cultured in liquid and streaked on solid media to determine colony morphotype and homogeneity. If both smooth and rough colony morphotypes were observed, these are colony purified and subsequently cultured and tested. If the slant appeared homogeneous, the liquid culture was used to screen again a panel of phages, determining the efficiency of plaquing (EOP) on the bacterial isolate relative to *Mycobacterium smegmatis* (control); each strain was given a GDxx identifier. Phages infecting with an EOP >0.1 were then tested in a killing assay over a range of bacterial phage concentrations and in a survival assay indicating the efficiency of killing and the likelihood of phage resistance emerging. The approximate timeline of screening is shown at left.

phage treatment are described below; detailed synopses are in the [Supplementary Information](#).

Favorable Clinical or Microbiological Responses

Favorable clinical and microbiological responses were observed in 5 patients (patients 1, 9, 10, 15, and 16) and partial clinical or microbiological responses were noted in 6 patients (patients 2, 4, 7, 13, 17, and 20) ([Table 1](#)); all were treated with IV phages except for patients 13 and 17, who also received nebulized phages after the IV regimen. Eight of these 11 patients

had CF and complex pulmonary infections (7 *M. abscessus*, 1 *M. avium*), 1 had disseminated skin lesions caused by *M. chelonae*, 1 had scleroderma with *M. abscessus* infection, and 1 had disseminated BCG infection ([Table 1](#)). In 5 patients (patients 9, 10, 15, 16, and 17), the infections appear to have been largely resolved: 3 with pulmonary *M. abscessus* infections (patients 9, 10, and 15), 1 with pulmonary *M. avium* infection (patient 17), and another with *M. chelonae* skin infection (patient 16); details of patients 15 and 16 were recently reported [[22](#), [23](#)]. Three of these 11 patients (patients 7, 16, and 17)

had no change in their antibiotic regimen during phage treatment, but at least 4 had some change to their antibiotic course. Patient 15 cleared *M. abscessus* cultures and successfully underwent a bilateral lung transplant. Two patients (1 and 13) had substantial clinical improvement, but without clear evidence of culture conversion. One of these (patient 1) was the case reported previously [5] in which posttransplant disseminated *M. abscessus* infection and clinical signs and symptoms greatly improved, but some skin nodules persisted after >1 year of phage treatment. These were only intermittently culture positive, but the patient subsequently died from CF-related health challenges and organ failure 44 months after the start of phage treatment. In the other (patient 13), there was substantial improvement of symptoms and forced expiratory volume in 1 second by spirometry, but the patient remained culture positive.

For 4 patients (patients 2, 4, 7, and 20), response to therapy was partial and more difficult to assess largely due to complications from other infections, although there was evidence of improved control of the *Mycobacterium* infections. One patient (patient 2) had a severe chest infection requiring sternum resection. Phage treatment resulted in AFB smear-negative chest swabs, but the patient died after failing therapy for multiple bacterial and fungal coinfections. For patient 4, phage treatment resulted in conversion to culture negative tracheal aspirates, but systemic adenovirus infection resulted in death. Patient 7 had *M. abscessus* infection with both rough and smooth colony morphotypes; the rough strain derived from the smooth strain by a mutation in glycopeptidolipid synthesis [17]. The phage identified for the rough strain (Table 1) did not infect the smooth counterpart but was administered on the possibility that removal of the rough variant could be clinically beneficial, even if the smooth strain persisted. The patient remained clinically stable but had persistently positive sputum cultures that grew only smooth strains after phage administration, suggesting that phage treatment had reduced the burden of the rough strain. Finally, patient 20 had MSMD and disseminated BCG infection. Phage treatment resulted in improved clinical signs and symptoms and marked reduction in BCG PCR positivity in weekly blood and urine samples. However, the patient died of other complications.

Inconclusive or Incomplete Outcomes

Five patients (patients 3, 8, 11, 12, and 18) had inconclusive responses to therapy or had modest short-lived improvements. Patient 8 developed phage neutralizing antibodies and had little clinical improvement with either aerosolized or IV administered phage, likely due to the phage neutralizing immune response. Like patient 7, patient 11 had a mixed infection with both rough and smooth colony morphotypes of *M. abscessus*, and active phage was identified only for the rough strain (Table 1). While chest radiographs improved, sputum cultures were intermittently positive. Patient 12 showed some reduction

in sputum *M. abscessus* load during the first month of IV administration, but subsequent recrudescence correlated temporarily with an increase in antibody-mediated phage neutralization [19]. Patient 18 has not shown substantial clinical improvement, likely also due to serum neutralization of phage; he has been switched to aerosolized phage therapy after 4 months of IV administration and treatment is ongoing. Patient 3 died shortly after the start of phage administration due to multiple organ failure.

No Clinical or Microbiological Improvement

Three patients with CF and 1 with non-CF bronchiectasis (patients 5, 6, 14, and 19), all with pulmonary *M. abscessus* infections, showed no overall clinical or microbiologic response (Table 1). All had been treated with IV phage, although 1 patient (patient 19) was switched to aerosolized administration. The reasons for lack of response are unclear.

Safety, Resistance, and Immunity

Phage administration by either IV or aerosolized routes was well-tolerated with no serious adverse reactions related to the phage in any patient. Phage preparations were highly purified, certified to be sterile, and had undetectable endotoxin levels, an advantage of using a lipopolysaccharide-free bacterial host (*M. smegmatis*) for phage growth. Eleven patients were treated with just a single phage (Table 1; 8 with Muddy, 3 with BPs Δ 33HTH_HRM^{GD03}), and in the 6 patients from whom rough colony *M. abscessus* isolates were recovered after the start of phage treatment, all remained fully phage sensitive. Indeed, changes in phage sensitivity were only observed in 1 phage in a cocktail of 3 (Table 2, patients 1 and 12).

Sera from 15 patients were tested for immune reactions, and robust neutralization of at least 1 phage was observed in 8 of the patients following IV treatment (Table 3). Although neutralization correlated temporally with loss of clinical response in patient 12 [19], there was no correlation between neutralization and outcomes in 8 remaining patients. Patients 8, 18, and 19 also developed neutralizing antibodies, plausibly contributing to reduction in therapeutic response, but strong neutralization to at least 1 of the phages in patients 15 and 16 did not prevent favorable or partial responses (Tables 1 and 3). Patient 1 had no phage neutralization until 2 years after starting therapy, when only 1 of the 3 phages had decreased activity in serum. Curiously, in some patients (patients 12, 15, and 16), pre-phage sera recognized the phages, although these were not neutralizing. Presumably, this reflects prior exposure to related but distinct phages in the environment.

DISCUSSION

This series of 20 patients treated with phages on a compassionate use basis provides support for further evaluation of phages

for treatment of mycobacterial infections. Phage administration was well-tolerated, and phage resistance was not observed even when using a single phage. Favorable responses were observed in more than half of the patients, including complete resolution of some infections, and successful lung transplantation in 1 patient. However, some patients saw little clinical benefit, and the basis for this variability in response is unclear. Although phage treatment of mycobacterial infections shows promise, this cohort illustrates some key limitations and lessons.

First, the repertoire of therapeutically useful phages is small, and expansion requires further phage isolation, developing phages induced from lysogenic strains or using synthetic phages [17, 24]. However, the lack of phage resistance (Table 2) supports use of a single phage, and where >1 phage is available, cycling their administration to circumvent neutralization. Second, optimal routes of phage administration and adequacy of tissue penetration are unclear. IV administration may be preferable for treatment of disseminated infections and appears effective for at least some lung infections, particularly when there is structural lung damage due to fibrosis, severe bronchiectasis, or mucoid plugging that compromises delivery by nebulization alone. We note that for patient 9, in whom the pulmonary *M. abscessus* infection was fully resolved, the phages were also deposited bronchoscopically, which may have contributed to more effective phage delivery to the infection. Nebulization may also avoid systemic neutralization. The immune status of the patient is also important; immunocompromised patients may tolerate extended phage administration without antibody-mediated neutralization. However, little is known about intracellular penetration or uptake of phages, particularly by macrophages, where most replicating mycobacteria are found. Third, dosage and regimens warrant optimization. As the treatments are well-tolerated, higher doses could be contemplated, using longer interdose intervals. Further exploration of pharmacodynamics and tissue penetration of phage is critical.

The lack of therapeutically useful phages for smooth *M. abscessus* strains, the unpredictable specificity for rough strains, and the limited phage repertoire represent current impediments to broad implementation of phage treatments. However, these limitations are not insurmountable, and these case studies suggest that phage treatments may be valuable tools for clinical control of NTM infections. Successful outcomes for *M. chelonae*, *M. avium*, and BCGosis, as well as *M. abscessus*, suggest a large spectrum of target *Mycobacterium* diseases.

Although compassionate use case studies such as these lack the rigor and consistency of treatment and patient monitoring possible in carefully controlled blinded clinical trials, they provide a wealth of insights for designing such trials. Variations in antibiotic regimens, surgical interventions, and management of coinfections can all potentially influence patient status, and direct linkage of phage treatments with outcomes in individual patients is perilous. Nonetheless, this series of case studies

strengthens the likelihood of direct benefits from phage treatments of *Mycobacterium* infections and the potential for infection control when none other is effective.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors are very grateful to our colleagues and collaborators including Owen Abad, Haley Aull, Lindsey Baden, Megan Clancy, Jonathan D’Cunha, Aleksandra Petrovic Fabijan, Katrina Ford, Melanie Forster, Alessia Franceschi, Will Garner, Kailey Hughes, Saija Kiljunen, Jon Koff, Ken Olivier, Eero Lauhkonen, Outi Lyytinen, Diana Pakstis, Crystal Petrone, Jenni Rosendahl, Aleksandra Theeba Thiruchelvam, and Hanna Vahtera. They also thank all of the faculty and student phage hunters in the SEA-PHAGES program who contributed to the phage collection used to identify therapeutically suitable phages.

Disclaimer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Financial support. This work was supported by the National Institutes of Health (NIH) (grant number GM131729), the Howard Hughes Medical Institute (grant number GT12053), and the Cystic Fibrosis Foundation (grant number HATFUL19GO). This work was also supported by a kind donation from the Fowler Fund for Phage Research to G. F. H; the National Heart, Lung, and Blood Institute (grant number K08 HL139994-01) and the Burroughs Wellcome Fund Career Award for Medical Scientists to K. A. C.; the NIH (HL146228) and the Cystic Fibrosis Foundation (grant numbers NICK20Y2-SVC and NICK20Y2-OUT) to J. A. N.; the NIH (grant number AI154546) to G. H; the Jane and Aatos Erkkö Foundation to M. S.; the Mallory Smith Legacy Fund and the University of California, San Diego Chancellor’s Fund to C. A. B. and R. T. S.; and the NIH (grant number R01HL146228) and Cystic Fibrosis Foundation (grant numbers NICK20Y2-SVC and NICK20Y2-OUT) to R. M. Da. (co-investigator).

Potential conflicts of interest. G. F. H. is a consultant for and receives grant support not directly related to this work from Janssen Pharmaceuticals (Collaborative Research Agreement); reports consulting fees from Janssen Inc and Tessera Inc; and reports presentation honoraria from the Pittsburgh Foundation and a leadership or fiduciary role with the Charles E. Kaufman Foundation scientific advisory board. R. M. De. and G. F. H. are co-inventors on patent applications related to the use of phages for treating nontuberculous mycobacterial (NTM) infections filed by the University of Pittsburgh of the Commonwealth System of Higher Education. D. v. D. is a consultant for Actavis, Tetrphase, Sanofi Pasteur, MedImmune, Astellas, Merck, Allergan, T2Biosystems, Roche, Achaogen, Neumedicine, Shionogi, Pfizer, Entasis, QPex, Wellspring, Karius, Melinta, and Utility; receives an editor’s stipend from British Society for Antimicrobial Chemotherapy; has received funding for unrelated projects from NIH, Merck, and Shionogi; reports payments for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Pfizer and Entasis; reports paid participation on a data and safety monitoring board (DSMB) or advisory board for Utility, Union, Entasis, and Merck; and reports a paid leadership or fiduciary role with the British Society for Antimicrobial Chemotherapy. K. A. C. has received consulting fees from Insmad (clinical trial site), Hillrom (clinical trial site), Paratek, Microbion, and AN2, and reports honoraria for a presentation from Insmad. G. H. receives grant support unrelated to this study from Karius, Allovir, and AstraZeneca, and reports participation on a DSMB or advisory board with Karius. R. T. S. is a paid consultant to Vir Biotechnology and to LysNtech; holds stock options in Antiva Biosciences and CytoDyn and stock or stock options with NoniGenex and Arcturus; previously served as an uncompensated member of the

AmpliPhi scientific advisory board; reports grants or contracts paid to institution from the National Institute of Allergy and Infectious Diseases; reports consulting fees from Pfizer, Semptra Energy, and Nurix; has patents planned, issued, or pending for orally bioavailable anti-coronavirus compounds; reports paid participation on DSMBs or advisory boards for Merck, Vlr Biosciences, SNIPR Biome, and Pardes Biosciences; and holds leadership or fiduciary roles with the International Antiviral Society (IAS)-USA and Specialists in Global Health. C. A. B. reports contracts to institution for clinical trials from Gilead and DNAe; payment to author for educational lectures from IAS-USA, Practice Point Communications (Optimal Management of HIV Disease and Hepatitis Clinical Conference [OPMAN] conference), and University of Arizona; has received payment for travel to the OPMAN conference from Practice Point Communications; served on a DSMB for ViiV/GlaxoSmith Kline; has held unpaid volunteer roles with IAS-USA and the Conference on Retroviruses and Opportunistic Infections Foundation Board; and has served as Deputy Editor/Associate Editor for the Infectious Diseases Society of America. A. K. reports the following grants or contracts unrelated to this work: National Health and Medical Research Council (NHMRC, Australia) Investigator Grant at Emerging Leadership 1 level, Conquer CF, Innovation Grant from Cystic Fibrosis Australia, Research Establishment Fellowship from the Royal Australasian College of Physicians and Research Award from the Australasian Society for Infectious Diseases (all paid to institution); payment to institution for grant application review for the Italian Cystic Fibrosis Research Foundation; unpaid role as member of DSMB for FluBubs (Safety and Immunogenicity of Early Quadrivalent Influenza Vaccine); unpaid leadership or fiduciary roles as Deputy Director (Clinical) of Phage Australia, pediatric infectious diseases research representative on the Australian Society for Infectious Diseases Clinical Research Network Steering Committee and the Australia and New Zealand Paediatric Infectious Diseases Group Executive Committee, member of the Sydney Children's Hospitals Network Human Research Ethics Committee Scientific Advisory Committee, and member of the Sydney Children's Hospitals Network Advanced Therapeutics Steering Committee. A. W. B. reports a role as a part-time employee of the Cystic Fibrosis Foundation, which provides some grant support to G. F. H.'s laboratory and, for the purposes of this manuscript, is the treating physician of one of the NTM patients in the cystic fibrosis clinic at Inova Fairfax Hospital. C. B. G. reports consulting fees from Advisory Janssen. B. J. M. reports an NHMRC Investigator Grant and philanthropic grant from the Curing Homesickness Foundation, both paid to institution and unrelated to this work; unpaid participation as member of the DSMB for the PATRIC trial; and unpaid position as board director of the Australasian Society for Infectious Diseases. M. G. T. O. reports a Cystic Fibrosis Foundation Adult Center Award and Cystic Fibrosis Foundation Therapeutic Development Center Award, unrelated to this work; support for attending meetings and/or travel, paid to University of Miami, from the Cystic Fibrosis Foundation Adult Center Award for attending North American Cystic Fibrosis Conference and a Cystic Fibrosis Foundation Therapeutic Development Center Award for attending the Therapeutics Development Network spring meeting; and an unpaid position as Cystic Fibrosis Lifestyle Foundation board member. J. I. reports an Investigator Grant (personal support) unrelated to this work from NHMRC. A. M. reports consulting fees paid to author as a member of the Air Liquide Advisory Board. J. A. N. reports contracts or grants unrelated to this work from the Cystic Fibrosis Foundation. M. S. reports funding on a project to set up a phage therapy laboratory in Finland, unrelated to this work, from the Jane and Aatos Erkkö Foundation. P. W. reports consulting fees from AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi Regeneron, and Vertex; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from AstraZeneca, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Vertex; and a leadership or fiduciary role with the Cystic Fibrosis Australia National Asthma Council of Australia. D. E. M. reports stock or stock options (no payments) with Moderna (1 share) and Pfizer (5 shares). R. M. Da. reports grants from the NIH unrelated to this work (grant number K01-AI125726 [principal investigator]). All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. *EBioMedicine* **2016**; 4:124–37.
- Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by *Pseudomonas aeruginosa* (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. *Lancet Infect Dis* **2019**; 19:35–45.
- Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for antibiotic-resistant bacterial infections. *Annu Rev Med* **2021**; 73:197–211.
- Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrob Agents Chemother* **2017**; 61:e00954-17.
- Dedrick R, Guerrero Bustamante C, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant *Mycobacterium abscessus*. *Nat Med* **2019**; 25:730–3.
- Aslam S, Lampley E, Wooten D, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. *Open Forum Infect Dis* **2020**; 7:ofaa389.
- Chan BK, Turner PE, Kim S, Mojibian HR, Eleftheriades JA, Narayan D. Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. *Evol Med Public Health* **2018**; 2018:60–6.
- Richards CJ, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis. *Semin Respir Crit Care Med* **2019**; 40:737–50.
- Martiniano SL, Esther CR, Haworth CS, Kasperbauer SH, Zemanick ET, Caverly LJ. Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. *Pediatr Pulmonol* **2020**; 55:521–5.
- Mustazzolu A, Venturelli L, Dinarelli S, et al. A rapid unraveling of the activity and antibiotic susceptibility of mycobacteria. *Antimicrob Agents Chemother* **2019**; 63:e02194-18.
- Griffith DE, Daley CL. Treatment of *Mycobacterium abscessus* pulmonary disease. *Chest* **2022**; 161:64–75.
- Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. *Semin Immunol* **2014**; 26:454–70.
- Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. *Semin Respir Crit Care Med* **2015**; 36:217–24.
- Chan BK, Stanley G, Modak M, Koff JL, Turner PE. Bacteriophage therapy for infections in CF. *Pediatr Pulmonol* **2021**; 56(Suppl 1):S4–9.
- Guerrero Bustamante C, Dedrick RM, Garlena RA, Russell DA, Hatfull GF. Towards a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse *Mycobacterium tuberculosis* strains. *mBio* **2021**; 12:e00973-21.
- Hatfull GF. Mycobacteriophages: windows into tuberculosis. *PLoS Pathog* **2014**; 10:e1003953.
- Dedrick RM, Smith BE, Garlena RA, et al. *Mycobacterium abscessus* strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. *mBio* **2021**; 12:e03431-20.
- Ruger K, Hampel A, Billig S, Rucker N, Suerbaum S, Bange FC. Characterization of rough and smooth morphotypes of *Mycobacterium abscessus* isolates from clinical specimens. *J Clin Microbiol* **2014**; 52:244–50.
- Dedrick RM, Freeman KG, Nguyen JA, et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary *Mycobacterium abscessus* infection. *Nat Med* **2021**; 27:1357–61.
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Clin Infect Dis* **2020**; 71:905–13.
- Guerrero-Bustamante CA, Dedrick RM, Garlena RA, Russell DA, Hatfull GF. Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse *Mycobacterium tuberculosis* strains. *mBio* **2021**; 12:e00973-21.
- Little JS, Dedrick RM, Freeman KG, et al. Bacteriophage treatment of disseminated cutaneous *Mycobacterium chelonae* infection. *Nat Commun* **2022**; 13:2313.
- Nick JA, Dedrick RM, Gray AL, et al. Host and pathogen response to bacteriophage engineered against *Mycobacterium abscessus* lung infection. *Cell* **2022**; 185:1860–74.e12.
- Dedrick RM, Aull HG, Jacobs-Sera D, et al. The prophage and plasmid mobilome as a likely driver of *Mycobacterium abscessus* diversity. *mBio* **2021**; 12:e03441-20.